[go: up one dir, main page]

WO2005030183A3 - Nouveau procede de preparation de comprimes de calcium d'atorvastatine - Google Patents

Nouveau procede de preparation de comprimes de calcium d'atorvastatine Download PDF

Info

Publication number
WO2005030183A3
WO2005030183A3 PCT/TR2004/000042 TR2004000042W WO2005030183A3 WO 2005030183 A3 WO2005030183 A3 WO 2005030183A3 TR 2004000042 W TR2004000042 W TR 2004000042W WO 2005030183 A3 WO2005030183 A3 WO 2005030183A3
Authority
WO
WIPO (PCT)
Prior art keywords
atorvastatin calcium
preparation
calcium tablets
formulation
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2004/000042
Other languages
English (en)
Other versions
WO2005030183A2 (fr
Inventor
Farshi Farhad Seyed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofarma Ilac Sanayi ve Ticaret AS
Original Assignee
Biofarma Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofarma Ilac Sanayi ve Ticaret AS filed Critical Biofarma Ilac Sanayi ve Ticaret AS
Publication of WO2005030183A2 publication Critical patent/WO2005030183A2/fr
Publication of WO2005030183A3 publication Critical patent/WO2005030183A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une formulation orale stable d'un composé inhibiteur de la HMG-CoA réductase du calcium d'atorvastatine à biodisponibilité améliorée. L'invention concerne un procédé de fabrication et une composition d'une telle formulation.
PCT/TR2004/000042 2003-09-26 2004-09-24 Nouveau procede de preparation de comprimes de calcium d'atorvastatine Ceased WO2005030183A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2003/01614A TR200301614A2 (tr) 2003-09-26 2003-09-26 Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem
TR2003/01614 2003-09-26

Publications (2)

Publication Number Publication Date
WO2005030183A2 WO2005030183A2 (fr) 2005-04-07
WO2005030183A3 true WO2005030183A3 (fr) 2005-09-09

Family

ID=34388831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2004/000042 Ceased WO2005030183A2 (fr) 2003-09-26 2004-09-24 Nouveau procede de preparation de comprimes de calcium d'atorvastatine

Country Status (2)

Country Link
TR (1) TR200301614A2 (fr)
WO (1) WO2005030183A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070520A1 (fr) 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Composition pharmaceutique comportant au moins un agent actif et un liant, qui gonfle dans un support acide
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
CN106420645A (zh) * 2016-11-24 2017-02-22 浙江新东港药业股份有限公司 一种含阿托伐他汀钙片及制备方法
CN108421045B (zh) * 2018-04-02 2021-09-24 北京海晶生物医药科技有限公司 一种阿托伐他汀钙组合物、制剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0789875A (ja) * 1993-09-20 1995-04-04 Dai Ichi Seiyaku Co Ltd 崩壊遅延防止錠剤
US5686104A (en) * 1993-01-19 1997-11-11 Warner-Lambert Company Stable oral CI-981 formulation and process of preparing same
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001080822A2 (fr) * 2000-04-20 2001-11-01 Ethypharm Granules effervescents et techniques de preparation
WO2002072073A2 (fr) * 2001-03-14 2002-09-19 Lek Pharmaceutical And Chemical Company D.D. Atorvastatine calcique sous forme pharmaceutique, composition de celle-ci et formulation pharmaceutique contenant de l'atorvastatine calcique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686104A (en) * 1993-01-19 1997-11-11 Warner-Lambert Company Stable oral CI-981 formulation and process of preparing same
JPH0789875A (ja) * 1993-09-20 1995-04-04 Dai Ichi Seiyaku Co Ltd 崩壊遅延防止錠剤
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001080822A2 (fr) * 2000-04-20 2001-11-01 Ethypharm Granules effervescents et techniques de preparation
WO2002072073A2 (fr) * 2001-03-14 2002-09-19 Lek Pharmaceutical And Chemical Company D.D. Atorvastatine calcique sous forme pharmaceutique, composition de celle-ci et formulation pharmaceutique contenant de l'atorvastatine calcique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 07 31 August 1995 (1995-08-31) *

Also Published As

Publication number Publication date
TR200301614A2 (tr) 2005-10-21
WO2005030183A2 (fr) 2005-04-07

Similar Documents

Publication Publication Date Title
WO2005014539A3 (fr) Inhibiteurs nouveaux de l'hmg-coa reductase a base de pyrrole
IL183920A0 (en) A COMBINATION FORMULATION OF A 3-HYDROXY-3 - METHYL GLUTARYL CoA REDUCTASE INHIBITOR AND AN ANTIHYPERTENSIVE AGENT AND PROCESSES FOR THE PREPARATION THEREOF
EP1205189A3 (fr) Compositions pharmaceutiques contenant des agonistes des prostaglandines et des inhibiteurs de HMG-CoA réductase pour une stimulation de la croissance osseuse
AU2003245313A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
IL163279A (en) Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
HUP0402590A3 (en) Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
AU2002337158A1 (en) Method for the production of adhesive stamped products
WO2004050618A8 (fr) Forme cristalline
AU2002349353A1 (en) Method for the production of pressure-sensitive adhesive stamped products
WO2005030183A3 (fr) Nouveau procede de preparation de comprimes de calcium d'atorvastatine
AU2003266397A1 (en) Method for the production of polyisobutene
WO2006134482A8 (fr) Procédé pour la fabrication d’atorvastatine, de ses sels pharmaceutiquement acceptables et de ses intermédiaires
WO2005105079A3 (fr) Nouveaux imidazoles
AU2003265373A1 (en) Preparation of aztreonam
AU2003246098A1 (en) Oxamidination process of carbonyl compounds
AU2002356423A1 (en) Process for the preparation of amorphous atorvastatin calcium
WO2007071012A8 (fr) Compositions pharmaceutiques stabilisees comprenant un inhibiteur de reductase hmg-coa
AU2003252358A1 (en) MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR
AU2003243432A1 (en) Process of making phosphordiamidite compounds
WO2006059210A3 (fr) Pyrrols bicycliques fusionnes comme inhibiteurs de la reductase as hmg-coa
HK1072421A (en) Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
AU2003263155A1 (en) Method for manufacture of dihydroisobenzofuran derivatives
AU2002337600A1 (en) Fed batch solid state fermentation for the production of hmg-coa reductase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase